Investigational · not FDA approved

Editorially reviewed · Last updated August 1, 2026 · How we review

TRIUMPH-3 Retatrutide Results: 22.6% at 12 mg

TRIUMPH-3: trial design, status, and results

Q: Have TRIUMPH-3 results been announced?

Yes. Lilly reported topline TRIUMPH-3 results on July 23, 2026: average weight loss of 22.6% at 12 mg and 21.6% at 9 mg at 80 weeks, versus 3.2% on placebo. ClinicalTrials.gov had not yet posted the registry results record, which typically follows a company announcement by months.

Q: How much weight did people lose in TRIUMPH-3?

An average of 22.6% at 12 mg (-55.8 lbs) and 21.6% at 9 mg (-52.7 lbs) at 80 weeks, versus 3.2% (-7.7 lbs) on placebo, on the efficacy estimand. Participants started at an average weight of 111.4 kg and BMI of 40.4 kg/m2.

Status: Reported · Phase 3 · 1,949 randomized · Week-80 primary endpoint · -22.6% weight loss at 12 mg

TRIUMPH-3 is Eli Lilly's Phase 3 trial of retatrutide in adults with severe obesity and established cardiovascular disease. Lilly reported topline results on July 23, 2026: the trial met its primary endpoint, with average weight loss of 22.6% at 12 mg and 21.6% at 9 mg at 80 weeks, versus 3.2% on placebo.

That makes it the first retatrutide Phase 3 readout in people who already have cardiovascular disease -- a sicker, higher-risk population than the general-obesity trial TRIUMPH-1.

Results (July 23, 2026)

Weight loss at 80 weeks (efficacy estimand):

Group	Weight Change	Average Loss
Retatrutide 9 mg	-21.6%	-52.7 lbs
Retatrutide 12 mg	-22.6%	-55.8 lbs
Placebo	-3.2%	-7.7 lbs

Participants entered the trial at an average weight of 111.4 kg and an average BMI of 40.4 kg/m2 -- the heaviest baseline population in the TRIUMPH program.

Cardiometabolic risk factors at 80 weeks (12 mg). Because this trial enrolled people who already have cardiovascular disease, Lilly reported a set of cardiometabolic secondaries alongside weight -- the only TRIUMPH readout so far to do so:

Measure	Average change at 12 mg
Triglycerides	-37.0%
High-sensitivity C-reactive protein (hsCRP)	-51.2%
Non-HDL cholesterol	-16.5%
Systolic blood pressure	-9.3 mmHg
Waist circumference	-7.5 in (19.0 cm)

Two caveats on reading these. Lilly published them only for the 12 mg arm -- there are no 9 mg values and no placebo comparators in the topline, so the share of each change attributable to the drug rather than to weight loss itself cannot be separated out here. And hsCRP is a marker of inflammation, not an outcome: halving it is a favorable direction, not a demonstrated reduction in cardiovascular events. The trial designed to test events is TRIUMPH-Outcomes, still running.

Safety and tolerability. The adverse-event profile was the gastrointestinal pattern seen across the program, at the doses studied here:

Adverse event	9 mg	12 mg	Placebo
Diarrhea	30.1%	24.4%	8.7%
Nausea	21.7%	22.4%	5.8%
Dysesthesia (altered skin sensation)	6.4%	6.4%	1.3%
Discontinued due to adverse events	9.8%	13.5%	4.8%

The 13.5% discontinuation rate at 12 mg runs above the equivalent rates in TRIUMPH-2 (7.7% at 12 mg) reported the same day. That is worth weighing honestly: this population is sicker than a general-obesity cohort, and a higher dropout rate in a sicker population is not the same signal as a higher dropout rate in a healthy one.

Cardiovascular events. Lilly also reported in-study event rates: a hazard ratio of 0.82 (95% CI 0.55-1.22) for five-component MACE and 1.12 (95% CI 0.64-1.96) for three-component MACE. Both confidence intervals cross 1.0, so neither is a statistically significant result, and the trial was never designed or powered to test cardiovascular outcomes. Read them as "nothing alarming appeared in a CVD population," not as evidence that retatrutide reduces cardiovascular events. The trial built to answer that question is the separate, event-driven TRIUMPH-Outcomes (NCT06383390), which is still running.

What is not in the topline. Lilly's release did not publish the treatment-regimen estimand figures, the 9 mg or placebo values behind the cardiometabolic secondaries above, HbA1c or physical-function results, serious-adverse-event rates, or subgroup results. Those come with full presentation or peer-reviewed publication, which had not happened as of the date on this page.

Source: Eli Lilly, "retatrutide successful in two additional Phase 3 obesity trials," July 23, 2026

Registry status

The ClinicalTrials.gov record for NCT05882045 lists:

Recruitment status: Completed
Registry results: Not yet posted (Lilly announced topline results separately on July 23, 2026)
Enrollment: 1,946 (actual, as recorded in the registry; Lilly's topline reports 1,949 randomized)
Study start: May 30, 2023
Primary completion: April 16, 2026
Study completion: May 14, 2026 (actual)
Primary outcome: Percent change from baseline in body weight at Week 80
Estimated study duration: About 113 weeks

A company topline announcement and a registry results posting are different things, and they usually arrive months apart. The numbers above come from Lilly's announcement; the registry record has not yet been updated with results.

Trial design

Property	Registered detail
ClinicalTrials.gov ID	NCT05882045
Sponsor	Eli Lilly and Company
Phase	3
Population	Adults with BMI ≥35 and established cardiovascular disease
Design	Randomized, double-blind, placebo-controlled, parallel assignment
Arms	Two retatrutide dose groups and placebo
Primary endpoint	Percent change in body weight from baseline at Week 80
Enrollment	1,946 (actual)

The trial studies weight-management efficacy and safety in a higher-risk cardiovascular population. It is distinct from TRIUMPH-Outcomes (NCT06383390), the event-driven trial designed to measure major cardiovascular and kidney outcomes.

Why TRIUMPH-3 matters

TRIUMPH-3 shows how retatrutide performs in people with established cardiovascular disease, a population not isolated in the 2023 Phase 2 obesity trial. Its registered secondary outcomes include waist circumference, blood pressure, lipids, HbA1c, fasting insulin, and physical function -- none of which were in the July 2026 topline.

Weight loss here (-22.6% at 12 mg) came in below the general-obesity trial TRIUMPH-1 (-28.3% at 12 mg at the same 80-week timepoint). Cross-trial comparisons are not apples to apples -- different populations, different baseline weight, different comorbidity burden -- but the direction matches what has been seen across this drug class: sicker, more medicated populations tend to lose somewhat less.

Where 24.2% came from

For years a 24.2% figure circulated attributed to TRIUMPH-3. It was real, but it belonged to a different trial.

Study	Phase	Population	Result
NCT04881760	2	Adults with obesity or overweight, without diabetes	24.2% mean weight loss at 48 weeks with 12 mg
TRIUMPH-3 (NCT05882045)	3	Adults with severe obesity and established cardiovascular disease	22.6% mean weight loss at 80 weeks with 12 mg (reported July 23, 2026)

The Phase 2 result was published in the New England Journal of Medicine in 2023. TRIUMPH-3 used a different population, protocol, and Week-80 primary endpoint -- so the Phase 2 number never applied to it, and the actual TRIUMPH-3 result landed lower, in a considerably sicker population.

What comes next

Lilly said it plans to submit a Biologics License Application (BLA) for retatrutide to the FDA in the first quarter of 2027. TRIUMPH-3 supports the weight-management filing in a cardiovascular-disease population; it is not the cardiovascular-outcomes evidence, which will come from TRIUMPH-Outcomes.

This page will be updated when fuller data appears in a primary source: a conference presentation, a peer-reviewed paper, or the ClinicalTrials.gov results record. For every other retatrutide readout, see the retatrutide trial tracker.

Frequently Asked Questions

Have TRIUMPH-3 results been announced?

Yes. Lilly reported topline TRIUMPH-3 results on July 23, 2026: average weight loss of 22.6% at 12 mg and 21.6% at 9 mg at 80 weeks, versus 3.2% on placebo. ClinicalTrials.gov had not yet posted the registry results record, which typically follows a company announcement by months.

How much weight did people lose in TRIUMPH-3?

An average of 22.6% at 12 mg (-55.8 lbs) and 21.6% at 9 mg (-52.7 lbs) at 80 weeks, versus 3.2% (-7.7 lbs) on placebo, on the efficacy estimand. Participants started at an average weight of 111.4 kg and BMI of 40.4 kg/m2.

Did TRIUMPH-3 report 24.2% weight loss?

No. The 24.2% result came from a separate Phase 2 obesity trial at 48 weeks and was never a TRIUMPH-3 number. The actual TRIUMPH-3 result, reported July 23, 2026, was 22.6% at 12 mg over 80 weeks.

Did TRIUMPH-3 show retatrutide reduces heart attacks or strokes?

No. Lilly reported in-study cardiovascular event rates — a hazard ratio of 0.82 (95% CI 0.55-1.22) for five-component MACE and 1.12 (95% CI 0.64-1.96) for three-component MACE — but both confidence intervals cross 1.0, and the trial was not powered to test cardiovascular outcomes. The trial designed to answer that question is TRIUMPH-Outcomes, which is still running.

Did TRIUMPH-3 improve triglycerides, cholesterol, or blood pressure?

Yes. At the 12 mg dose Lilly reported average reductions of 37.0% in triglycerides, 51.2% in hsCRP (a marker of inflammation), 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure, and 7.5 inches (19.0 cm) in waist circumference at 80 weeks. These were published only for the 12 mg arm — the topline gives no 9 mg or placebo comparators, so how much of each change is the drug rather than the weight loss itself is not separable from these figures. Improving a risk marker is also not the same as preventing an event; that is what TRIUMPH-Outcomes is built to test.

What is the TRIUMPH-3 primary endpoint?

The registered primary endpoint is percent change from baseline in body weight at Week 80.

Is TRIUMPH-3 a cardiovascular outcomes trial?

No. It studies weight management in people with established cardiovascular disease. The separate TRIUMPH-Outcomes trial measures major cardiovascular and kidney events.

Sources

TRIUMPH-3 study record (NCT05882045) — ClinicalTrials.gov
TRIUMPH-3 trial page — Eli Lilly and Company
Phase 2 obesity trial — New England Journal of Medicine, 2023

Medical disclaimer: Retatrutide is investigational and is not FDA approved. This page is informational only and is not medical advice. glp3.wiki is not affiliated with Eli Lilly or any pharmaceutical company.

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

TRIUMPH-3 (NCT05882045)
ClinicalTrials.gov
TRIUMPH-3 trial page
Eli Lilly

Grounded in primary sources

NEJM

The Lancet

JAMA

FDA

ClinicalTrials.gov

Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker

Living tracker of every retatrutide trial — TRIUMPH-1/2/3/4/5, TRIUMPH-Outcomes, TRANSCEND-T2D-1/2, and SYNERGY-OUTCOMES Phase 3 readouts.

Tracker

Retatrutide FDA Approval Timeline 2026-2028

Lilly plans a Q1 2027 BLA filing. TRIUMPH-1, -2 and -3 have reported. Approval window late 2027–28.

Explainer

Retatrutide for Knee Osteoarthritis: TRIUMPH-4

TRIUMPH-4, the first retatrutide Phase 3 readout (December 2025), showed 28.7% weight loss and 75.8% pain reduction in adults with obesity and knee osteoarthritis.

News

TRANSCEND-T2D-1: Retatrutide Phase 3 Diabetes Results (March 2026)

First Phase 3 retatrutide trial in type 2 diabetes — 16.8% weight loss and -2.0% A1C at 12 mg over 40 weeks. Announced March 19, 2026.

Safety

Retatrutide Side Effects & Safety Data (2026)

Trial incidence for retatrutide (reta) side effects — GI rates, dysesthesia, and class-level safety concerns.